Chronic graft-versus-host-disease
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e307Keywords:
Hematopoietic Cell Transplantation, Chronic Graft-Versus-Host-Disease, Risk Factors, Prophylaxis, ManagementAbstract
Chronic GvHD is a major cause of non-relapse morbidity and mortality after hematopoietic cell transplantation. Its incidence has increased due to more frequent use of unrelated and/or mismatched donors, reduced intensity conditioning regimens or intensified regimens and PBSC grafts. The first-line therapy for chronic GvHD is systemic corticosteroids associated with either CNI or sirolimus, as a steroid sparing agent. Since children are more susceptible to the long-term steroid side effects, development of steroid-free strategies for front-line therapy is crucial. Sirolimus seems to be an interesting choice due to its capacity of inhibiting T-cells preserving the Tregs cells and antifibrotic, antineoplastic and antiviral activities. FAM regimen (Fluticasone, Azitromycin and Montelucaste) is recommended in combination with systemic steroids for initial treatment of bronchiolitis obliterans. For steroid-refractory chronic GvHD, ruxolitinib is the standard of care, while extracorporeal photopheresis can be combined for better results, however treatment costs are limitations. Extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned above in severe chronic GvHD. Since access to novel drugs and extracorporeal photopheresis or mesenchymal stem cells is tough, other options approved for the third line and beyond are ibrutinib, belumosudil and axatilimab. Conventional agents could be used such as imatinib, low dose-MTX, rituximab, however the expected response rates are lower. We reviewed clinical studies and published recommendations on pediatric chronic GVHD that were presented in debate rounds with GvHD experts of the Pediatric group of the Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO). The goal of this consensus is to standardize the prophylaxis, diagnosis, grading and treatment of chronic GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
References
1. Sobkowiak-Sobierajska A, Lindemans C, Sykora T, Wachowiak J, Dalle JH, Bonig H, Gennery A, Lawitschka A. Management of chronic graft-vs.-host disease in children and adolescents with ALL: present status and model for a personalised management plan. Front Pediatr. 2022;10:808103. https://doi.org/10.3389/fped.2022.808103
2. Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, Lachance S, Deotare U, White J, Elemary M, Jamani K, Fraga C, Lemieux C, Novitzky-Basso I, Law AD, Kumar R, Walker I, Schultz KR; CTTC Chronic GVHD Guideline Working Group. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for management and treatment of chronic graft-versus-host disease and future directions for development. Curr Oncol. 2024;31(3):1426–44. https://doi.org/10.3390/curroncol31030108
3. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001
4. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, Kreft A, Longerich T, Morton T, Myerson D, Prieto VG, Rosenberg A, Treister N, Washington K, Ziemer M, Pavletic SZ, Lee SJ, Flowers ME, Schultz KR, Jagasia M, Martin PJ, Vogelsang GB, Kleiner DE. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant. 2015;21(4):589–603. https://doi.org/10.1016/j.bbmt.2014.12.031
5. Shi CR, Ferreira AL, Kaur M, Xiang D, Caputo J, Choe HK, Hamad N, Cowen EW, Kaffenberger BH, Baumrin E. Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care. Transplant Cell Ther. 2024;30(9S):S513–33. https://doi.org/10.1016/j.jtct.2024.05.020
6. Dean D, Sroussi H. Oral chronic graft-versus-host disease. Front Oral Health. 2022;3:903154. https://doi.org/10.3389/froh.2022.903154
7. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D, Goyal RK, Jackson MA, Katz J, Kim T, Majmudar PA, Malhotra RP, McDonald MB, Rajpal RK, Raviv T, Rowen S, Shamie N, Solomon JD, Stonecipher K, Tauber S, Trattler W, Walter KA, Waring GO 4th, Weinstock RJ, Wiley WF, Yeu E. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017; 27(Suppl. 1):3–47. https://doi.org/10.1097/01.icu.0000512373.81749.b7
8. Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016;7(Suppl. 1):S21–31. https://doi.org/10.3978/j.issn.2078-6891.2015.036
9. Machado AMN, Hamerschlak N, Rodrigues M, Piccinato C de A, Podgaec S, Mauad LMQ. Female genital tract chronic graft-versus-host disease: A narrative review. Hematol Transfus Cell Ther. 2019;41(1):69–75. https://doi.org/10.1016/j.htct.2018.06.005
10. Fraebel J, Engelhardt BG, Kim TK. Non-infectious pulmonary complications after hematopoietic stem cell transplantation. Transplant Cell Ther. 2023;29(2):82–93. https://doi.org/10.1016/j.jtct.2022.11.012
11. Hockenbery DM, Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation: stem cell transplantation. Wiley; 2015. p. 1140–60. https://doi.org/10.1002/9781118416426.ch94
12. Limaye S, Limaye V. Clinical characteristics of myositis associated with graft-versus-host disease. Curr Rheumatol Rep. 2021;23(5):30. https://doi.org/10.1007/s11926-021-00996-x
13. Cuvelier GDE, Schoettler M, Buxbaum NP, Pinal-Fernandez I, Schmalzing M, Distler JHW, Penack O, Santomasso BD, Zeiser R, Angstwurm K, MacDonald KPA, Kimberly WT, Taylor N, Bilic E, Banas B, Buettner-Herold M, Sinha N, Greinix HT, Pidala J, Schultz KR, Williams KM, Inamoto Y, Cutler C, Griffith LM, Lee SJ, Sarantopoulos S, Pavletic SZ, Wolff D. Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 National Institutes of Health Consensus Project Task Force. Transplant Cell Ther. 2022;28(8):426–45. https://doi.org/10.1016/j.jtct.2022.05.038
14. Doering J, Perl M, Weber D, Banas B, Schulz C, Hamer OW, Angstwurm K, Holler E, Herr W, Edinger M, Wolff D, Fante MA. Incidence and outcome of atypical manifestations of chronic graft-versus-host disease: results from a retrospective single-center analysis. Transplant Cell Ther. 2023;29(12):772.e1–e10. https://doi.org/10.1016/j.jtct.2023.09.016
15. Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, Lachance S, Deotare U, White J, Elemary M, Jamani K, Fraga C, Lemieux C, Novitzky-Basso I, Law AD, Kumar R, Walker I, Schultz KR; CTTC Chronic GVHD Guideline Working Group. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for management and treatment of chronic graft-versus-host disease and future directions for development. Curr Oncol. 2024;31(3):1426–44. https://doi.org/10.3390/curroncol31030108
16. Malard F, Mohty M. Updates in chronic graft-versus-host disease management. Am J Hematol. 2023; 98(10):1637–44. https://doi.org/10.1002/ajh.27040
17. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–34. https://doi.org/10.1016/j.bbmt.2016.09.023
18. Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–79. https://doi.org/10.1056/nejmra1703472
19. Inagaki J, Moritake H, Nishikawa T, Hyakuna N, Okada M, Suenobu S, Nagai K, Honda Y, Shimomura M, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J. Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(11):1973–80. https://doi.org/10.1016/j.bbmt.2015.07.025
20. Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management. J Am Acad Dermatol. 2024;90(1):19–36. https://doi.org/10.1016/j.jaad.2022.12.023
21. Markova A, Pan A, Dusza S, Chowdhury A, Kukoyi O, Perales M-A, Lacouture M, Prockop S, Ponce DM. Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Blood. 2021;138(Suppl. 1):3915. https://doi.org/10.1182/blood-2021-144743
22. Belmesk L, Hatami A, Powell J, Kokta V, Coulombe J. Successful use of dupilumab in recalcitrant pediatric atopic dermatitis-like graft-versus-host disease: A case series. JAAD Case Rep. 2023;44:11–6. https://doi.org/10.1016/j.jdcr.2023.11.003
23. Hardy JM, Marguery MC, Huynh A, Borel C, Apoil PA, Lamant L, Tournier E, Alberto C, Pauwels C, Thomas M, Mazereeuw Hautier J, Paul C, Bulai Livideanu C. Photo-induced graft-versus-host disease. Photodermatol Photoimmunol Photomed. 2016;32(5-6):291–5. https://doi.org/10.1111/phpp.12273
24. Li EB, Song JS, Huang JT, Hawryluk EB, London WB, Guo D, Sridharan M, Fisher DE, Rea CJ, Lehmann LE, Duncan CN. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: a survey-based cross-sectional cohort study. Pediatr Dermatol. 2019;36(6):882–6. https://doi.org/10.1111/pde.13984
25. D’Arcy ME, Pfeiffer RM, Rivera DR, Hess GP, Cahoon EK, Arron ST, Brownell I, Cowen EW, Israni AK, Triplette MA, Yanik EL, Engels EA. Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States. JAMA Dermatol. 2020;156(7):772–9. https://doi.org/10.1001/jamadermatol.2020.1141
26. Silva M, Martins JC, Souza PK. Adjuvant dermatological therapy. J Bone Marrow Transplant Cell Ther. 2023:4(1):190. https://doi.org/10.46765/2675-374X.2023v4n1p190
27. Ballester-Sánchez R, Navarro-Mira MÁ, de Unamuno-Bustos B, Pujol-Marco C, Sanz-Caballer J, Botella-Estrada R. The role of phototherapy in cutaneous chronic graft-vs-host disease: a retrospective study and review of the literature. Actas Dermosifiliogr. 2015;106(8):651–7. https://doi.org/10.1016/j.ad.2015.04.009
28. Garbutcheon-Singh KB, Fernández-Peñas P. Phototherapy for the treatment of cutaneous graft versus host disease. Australas J Dermatol. 2015;56(2):93–9. https://doi.org/10.1111/ajd.12191
29. Feldstein JV, Bolaños-Meade J, Anders VL, Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol. 2011;65(4):733–8. https://doi.org/10.1016/j.jaad.2010.08.006
30. Treister N, Li S, Lerman MA, Lee S, Soiffer R. Narrow-band UVB phototherapy for management of oral chronic graft-versus-host disease. Photodermatol Photoimmunol Photomed. 2015;31(2):75–82. https://doi.org/10.1111/phpp.12141
31. Sokolova A, Lee A, D Smith S. The safety and efficacy of narrow band ultraviolet B treatment in dermatology: a review. Am J Clin Dermatol. 2015;16(6):501–31. https://doi.org/10.1007/s40257-015-0151-7
32. Zhang M, Qureshi AA, Geller AC, Frazier L, Hunter DJ, Han J. Use of tanning beds and incidence of skin cancer. J Clin Oncol. 2012;30(14):1588–93. https://doi.org/10.1200/JCO.2011.39.3652
33. Wolff D, Fatobene G, Rocha V, Kröger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transplant. 2021;56(9): 2079–87. https://doi.org/10.1038/s41409-021-01389-5
34. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med.2021; 385(3): 228–38. https://doi.org/10.1056/NEJMoa2033122
35. Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, Martin PJ. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013; 121(12): 2340–6. https://doi.org/10.1182/blood-2012-11-465583
36. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062–8. https://doi.org/10.1038/leu.2015.212
37. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739–49. https://doi.org/10.1182/blood.2020004823
38. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–50. https://doi.org/10.1182/blood-2017-07-793786
39. Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Transplant. 2019; 25(10):2002–7. https://doi.org/10.1016/j.bbmt.2019.06.023
40. Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood. 2019;133(11):1191–200. https://doi.org/10.1182/blood-2018-04-785899
41. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074–80. https://doi.org/10.1182/blood-2005-09-3907
42. Oarbeascoa G, Lozano ML, Guerra LM, Amunarriz C, Saavedra CA, Garcia-Gala JM, Viejo A, Revilla N, Fleitas CA, Arroyo JL, Revuelta EM, Galego A, Hernandez-Maraver D, Kwon M, Diez-Martin J, Pascual C. Retrospective multicenter study of extracorporeal photopheresis in steroid-refractory acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(4):651–8. https://doi.org/10.1016/j.bbmt.2019.12.769
43. Linn SM, Novitzky-Basso I, Patriquin C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure. Leuk Res. 2023;134:107387. https://doi.org/10.1016/j.leukres.2023.107387
44. Novitzky-Basso I, Patriquin C, Linn SM, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in thirdline or beyond treatment for chronic GvHD. Transplant Cell Ther. 2023;29(12):773.e1–e10. https://doi.org/10.1016/j.jtct.2023.09.021
45. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–15. https://doi.org/10.1182/blood-2014-08-551994
46. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73(1):56–61. https://doi.org/10.1111/j.1600-0609.2004.00247.x
47. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756–62. https://doi.org/10.1182/blood-2006-01-0233
48. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2016;22(2):319–27. https://doi.org/10.1158/1078-0432.CCR-15-1443
49. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7. https://doi.org/10.1038/sj.bmt.1705725
50. Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A, Caballero D, Sierra J, Ribera JM, Díez JL. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versushost disease. Biol Blood Marrow Transplant. 2007;13(6):701–6. https://doi.org/10.1016/j.bbmt.2007.02.003
51. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(1):47–55. https://doi.org/10.1016/j.bbmt.2004.10.004
52. Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J, Einsele H, Grigoleit GU, Holler E, Wolff D. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant. 2014;49(11):1412–8. https://doi.org/10.1038/bmt.2014.170
53. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18. https://doi.org/10.1182/blood-2009-02-204156
54. Mayer J, Krejcí M, Doubek M, Pospísil Z, Brychtová Y, Tomíska M, Rácil Z. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant. 2005;35(7):699–705. https://doi.org/10.1038/sj.bmt.1704829
55. Chao NJ, Foster YG, Rowe K, Shah A, Cardones AR. Pulse cyclophosphamide for steroid-refractory chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 2016;22(3 Suppl.):S393–5. https://doi.org/10.1016/j.bbmt.2015.11.918
56. Fante MA, Holler B, Weber D, Angstwurm K, Bergler T, Holler E, Edinger M, Herr W, Wertheimer T, Wolff D. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. Ann Hematol. 2020;99(9):2181–90. https://doi.org/10.1007/s00277-020-04193-1
57. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278–89. https://doi.org/10.1182/blood.2021012021
58. Hautmann AH, Wolff D, Hilgendorf I, Fehn U, Edinger M, Hoffmann P, Herr W, Kölbl O, Holler B, Sporrer D, Holler E, Hautmann MG. Total nodal irradiation in patients with severe treatment-refractory chronic graftversus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. Radiother Oncol. 2015;116(2):287–93. https://doi.org/10.1016/j.radonc.2015.07.035
59. Peyraga G, Lizee T, Gustin P, Clement-Colmou K, Di Bartolo C, Supiot S, Mahe MA, François S, Mege M. Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI). Clin Transplant. 2017;31(4). https://doi.org/10.1111/ctr.12923
60. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45(12):1732–40. https://doi.org/10.1038/bmt.2010.195
61. Morata-Tarifa C, Macías-Sánchez MDM, Gutiérrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther. 2020;11(1):64. https://doi.org/10.1186/s13287-020-01592-z
62. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NK, Wagner J, Enright H. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26(8):865–9. https://doi.org/10.1038/sj.bmt.1702626
63. Koshy AG, Kim HT, Liegel J, Arnason J, Ho VT, Antin JH, Joyce R, Cutler C, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson S, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023;141(24):2932–43. https://doi.org/10.1182/blood.2022019107
64. Pidala J, Bhatt VR, Hamilton B, Pusic I, Wood WA, Onstad L, Hall AM, Storer B, Lee SJ. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial. Biol Blood Marrow Transplant. 2020;26(9):1612–9. https://doi.org/10.1016/j.bbmt.2020.05.015
65. Holtzman NG, Im A, Ostojic A, Curtis LM, Parsons-Wandell L, Nashed J, Peer C, Figg WD, Magone MT, Coewn EW, Mays JW, Hakim FT, Rose JJ, Pouzelles MC, Taylor N, Pavletic SZ. Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study. Abstract 357. Blood. 2020;136(Suppl. 1):1–11. https://doi.org/10.1182/blood-2020-140392
66. Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I/II study. J Clin Oncol. 2023;41(10):1864–75. https://doi.org/10.1200/JCO.22.00958
67. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O’Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Axatilimab in recurrent or refractory chronic graft-versushost disease. N Engl J Med. 2024;391(11):1002–14. https://doi.org/10.1056/NEJMoa2401537
68. Velickovic VM, McIlwaine E, Zhang R, Spelman T. Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review. Ther Adv Hematol. 2020;11:2040620720977039. https://doi.org/10.1177/2040620720977039
69. Shreberk-Hassidim R, Neumark M, Greenberger S, Goldstein G, Hassidim A, Dukler Y, Maly A, Stepensky P, Molho-Pessach V. Cutaneous chronic graft versus host disease following allogeneic haematopoietic stem cell transplantation in children: a retrospective study. Acta Derm Venereol. 2018;98(2):206–11. https://doi.org/10.2340/00015555-2824
70. Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147–e159. https://doi.org/10.1016/S2352-3026(23)00342-3
71. Luo C, Huang X, Wei L, Wu G, Huang Y, Ding Y, Huang Z, Chen J, Li X, Zou Y, Xu S. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023;14:1211171. https://doi.org/10.3389/fimmu.2023.1211171
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Adriana Mello Rodrigues, Rita de Cassia Barbosa da Silva Tavares, Antonio Vaz de Macedo, Carla Nolasco Monteiro Breviglieri, Marcia de Matos Silva, Mônica Alves, Rafaela de Souza Ferreira, Roseane Vasconcelos Gouveia, Luis Fernando Bouzas
This work is licensed under a Creative Commons Attribution 4.0 International License.
